Illumina (ILMN) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue was $1.08 billion, in line with expectations, with strong margin and earnings expansion driven by operational excellence and cost discipline.

• Non-GAAP operating margin was 22.6% and diluted EPS was $1.14, both exceeding guidance.

• NovaSeq X adoption accelerated, with over 55% of high-throughput gigabases sequenced on X and cumulative NovaSeq X revenue surpassing $1 billion.

• GRAIL was spun off in June 2024, with 85.5% of shares distributed to stockholders and 14.5% retained.

• The company launched the MiSeq i100 and announced further innovations, including comprehensive whole genome sequencing and five-base genome technology.

Financial highlights

• Sequencing consumables revenue grew 7% year-over-year to $741 million, offsetting a 42% decline in sequencing instruments revenue.

• Total sequencing gigabase output grew over 40% year-over-year.

• Non-GAAP gross margin increased 450 basis points year-over-year to 70.5%, driven by productivity improvements and favorable revenue mix.

• Free cash flow was $284 million, with $316 million in cash flow from operations.

• Q3 2024 net income was $705 million GAAP and $181 million non-GAAP.

Outlook and guidance

• Full-year 2024 revenue is expected to decline approximately 3%, with Q4 revenue projected at $1.07 billion.

• Non-GAAP operating margin guidance raised to 21%-21.5% for 2024; non-GAAP diluted EPS guidance increased to $4.05-$4.15.

• Instrument revenue is forecasted to decline in the mid-30% range versus 2023, while consumables revenue is expected to grow toward the upper end of low single digits.

• Positive growth is anticipated in 2025, with a return to high single-digit revenue growth by 2027.